With sequence data for hundreds of advanced breast cancer samples, investigators identified genetic alterations shared with — and distinct from — those in primary tumors.
As part of their MI-ONCOSEQ Program, Michigan researchers examined the mutational and transcriptional landscape of 500 metastatic tumors.
Neon Therapeutics is sponsoring a Phase Ib trial of neoantigen-based vaccines in combination with anti-PD-1 treatment in melanoma, lung cancer, and bladder cancer.
New research has identified circulating cell subtypes with ties to better or worse outcomes in individuals with prostate cancer.
In 86 pretreated cancer patients with mismatch repair deficiency, researchers saw objective response rates exceeding 50 percent after anti-PD-1 immunotherapy.
The researchers described gut microbial diversity and composition differences in metastatic melanoma patients who did or did not respond to immunotherapy.
The company plans to outlicense the assay, developed using a custom Affymetrix microarray, to an interested partner.
Analyses of T cell therapy-responsive metastatic HPV-positive cervical cancers suggest the immune cells largely respond to tumor rather than viral antigens.
With new research and commercial test launches, clincians anticipate exciting new tools but judging quality and utility has become challenging.
The firm has launched a yearly subscription program that includes quarterly blood tests to look for genetic and proteomic signs of metastasis or cancer recurrence.
New Mexico is re-doing its proposed science education standards after criticism, the Associated Press reports.
Agbio executives say gene editing will speed up breeding efforts, according to the Wall Street Journal.
La Trobe University's Jenny Graves has won the $250,000 Prime Minister's Prize for Science, the Guardian reports.
In Cell this week: post-treatment changes to melanoma genome, multi-omics analysis of muscle-invasive bladder cancer, and more.